Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2010 - 2026)
Rigel Pharmaceuticals' (RIGL) quarterly Income from Continuing Operations came in at 8654000.0 in Q1 2026, down 24.39% year-on-year from 11446000.0 in Q1 2025, and down 96.77% quarter-over-quarter from 268065000.0 in Q4 2025.
Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 8654000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 24.39% year-over-year to 8654000.0 in Q1 2026; TTM through Mar 2026 was 364232000.0, a 879.7% increase from a year earlier, with the FY2025 full-year figure at 367024000.0, up 1999.08% from the prior year.
- Income from Continuing Operations slipped to 8654000.0 in Q1 2026 per RIGL's latest filing, from 268065000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 268065000.0 in Q4 2025 and bottomed at 27445000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 11000.0 (2023), against an average of 18141058.82.
- Across the five-year window, Income from Continuing Operations plunged 169.53% in 2022 and surged 130272.73% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 1401000.0 in 2022, then plunged by 99.21% to 11000.0 in 2023, then jumped by 130272.73% to 14341000.0 in 2024, then surged by 1769.22% to 268065000.0 in 2025, then plunged by 96.77% to 8654000.0 in 2026.
- Per Business Quant, the three latest RIGL Income from Continuing Operations figures stand at 8654000.0 (Q1 2026), 268065000.0 (Q4 2025), and 27900000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Rigel Pharmaceuticals | 674.25 Mn | 527.57 Mn | 54.21 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.65 Mn |
| Dec 31, 2025 | 268.07 Mn |
| Sep 30, 2025 | 27.90 Mn |
| Jun 30, 2025 | 59.61 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | 14.34 Mn |
| Sep 30, 2024 | 12.42 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | -8.25 Mn |
| Dec 31, 2023 | 11,000.00 |
| Sep 30, 2023 | -5.69 Mn |
| Jun 30, 2023 | -6.60 Mn |
| Mar 31, 2023 | -13.91 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | -19.04 Mn |
| Jun 30, 2022 | -13.49 Mn |
| Mar 31, 2022 | -27.45 Mn |
| Dec 31, 2021 | -22.61 Mn |
| Sep 30, 2021 | -20.95 Mn |
| Jun 30, 2021 | -13.79 Mn |